Global ETD Search

Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.

Results

Showing 1 to 20 of 252 for “"Docetaxel"”.

  1. A multi-compartment pharmacokinetic model of docetaxel

    Docetaxel is a clinically active chemotherapeutic agent commonly used in the treatment of solid tumors. It is administered within a micelle encapsulation, polysorbate 80, via intravenous infusion. Docetaxel is known to have a high degree of interpatient variability in its pharmacokinetic behaviour. …

    lethbridge Repository record for A multi-compartment pharmacokinetic model of docetaxel (opens in a new tab)

  2. Docetaxel uptake and modulation of P-gpmediated docetaxel efflux by tyrosine kinase inhibitors in human lung carcinoma cell lines

    Treatment with the taxanes, docetaxel and paclitaxel, can result in the emergence of multi-drug resistance (MDR) mediated by P-gp (MDR-1, ABCB1), which is an effective cellular efflux pump for both agents. This thesis was undertaken to examine the contribution of drug transport mechanisms to …

    dcu Repository record for Docetaxel uptake and modulation of P-gpmediated docetaxel efflux by tyrosine kinase inhibitors in human lung carcinoma cell lines (opens in a new tab) Download PDF for Docetaxel uptake and modulation of P-gpmediated docetaxel efflux by tyrosine kinase inhibitors in human lung carcinoma cell lines (opens in a new tab)

  3. Residual breast cancer metabolic phenotype after docetaxel treatment

    … of residual breast cancer which survived docetaxel treatment, \(in\) \(vitro\) and \(in\) \(vivo\), quantifying polar metabolite levels and conducting pathway tracing and metabolic flux analysis using stable isotope (\(^{13}\)C) labelled tracers. \(In\) \(vitro\) residual cells presented a …

    birmingham Download PDF for Residual breast cancer metabolic phenotype after docetaxel treatment (opens in a new tab)

  4. Characterisation of Docetaxel-Resistance in Castrate Resistant Prostate Cancer

    … (CRPC) being the lethal stage of the disease. Docetaxel-based chemotherapy is the standard-of-care for CRPC patients. Inevitably, those patients who respond, develop resistance to chemotherapy. Limited success of clinical trials emanating from conventional candidate-based approaches highlights …

    unsw Repository record for Characterisation of Docetaxel-Resistance in Castrate Resistant Prostate Cancer (opens in a new tab)

  5. Bladder tissue distribution of paclitaxel and docetaxel from polymeric nanoparticles

    Taxane based drugs are commonly used second-line adjuvant therapies for the treatment of superficial bladder cancer. However, the effectiveness of these drugs following intravesical instillation is limited, because of a short drug residence time and poor drug penetration into the bladder wall. The …

    ubc Repository record for Bladder tissue distribution of paclitaxel and docetaxel from polymeric nanoparticles (opens in a new tab) Download PDF for Bladder tissue distribution of paclitaxel and docetaxel from polymeric nanoparticles (opens in a new tab)

  6. Verläufe ambulanter Docetaxel-Firstline-Chemotherapien bei Patienten mit kastrationsresistentem Prostatakarzinom

    Einleitung: Docetaxel ist ein etabliertes Chemotherapeutikum beim kastrationsresistenten Prostatakazinom (CRPCa), da es zu einer Verlängerung des Gesamtüberlebens führt (Tannock IF et al. 2004, Petrylak DP et al. 2004). In der klinischen Praxis liegen jedoch differente Bedingungen im Vergleich zu …

    fu-berlin Repository record for Verläufe ambulanter Docetaxel-Firstline-Chemotherapien bei Patienten mit kastrationsresistentem Prostatakarzinom (opens in a new tab)

  7. Biodistribuição de samário -153- EDTMP em ratos TRATADOS com docetaxel

    … fosfonato (EDTMP-153Sm). O docetaxel, um taxano com ação sobre tumores avançados de mama e próstata, tem-se apresentado como uma nova opção de tratamento quimioterápico. Muitos pacientes fazem uso simultâneo de EDTMP-153Sm e docetaxel. Este estudo procurou avaliar a …

    brazil-ufrn Repository record for Biodistribuição de samário -153- EDTMP em ratos TRATADOS com docetaxel (opens in a new tab)

  8. Targeted chemotherapy: Trastuzumab tailored Docetaxel loaded PLGA nanoaparticles for HER2 positive breast cancer

    … rationale of using trastuzumab (TmAb) tailored docetaxel (Doc) loaded poly-D, L-lactide-co-glycolide (PLGA) nanoparticles (NPs) to target the human epidermal receptor-2 (HER2) receptors of breast cancer cells. Utilizing emulsification solvent evaporation technique, pre-activated drug loaded NPs …

    sask Repository record for Targeted chemotherapy: Trastuzumab tailored Docetaxel loaded PLGA nanoaparticles for HER2 positive breast cancer (opens in a new tab)

  9. Modulation of nanoparticle uptake, intracellular distribution, and retention with docetaxel to enhance radiotherapy

    … tumor. We chose gold nanoparticles (GNPs) and docetaxel (DTX) as our choice of two radiosensitizing agents. They have a different mechanism of action which could lead to synergistic effect. Our first goal was to assess the variation in GNP uptake, distribution, and retention in the presence of …

    uvic Repository record for Modulation of nanoparticle uptake, intracellular distribution, and retention with docetaxel to enhance radiotherapy (opens in a new tab)

  10. Optimization of Survivin Dimerization Inhibitors for the Treatment of Docetaxel-Resistant Prostate Cancer

    … common cause of cancer-related mortality in men. Docetaxel is the first cytotoxic agent to show modest improvements in overall survival rate in patients with metastatic prostate cancer. Unfortunately, over half of these patients do not respond to treatment and ultimately all develop resistance. …

    iupui Repository record for Optimization of Survivin Dimerization Inhibitors for the Treatment of Docetaxel-Resistant Prostate Cancer (opens in a new tab)

  11. Potential use of Aneustat for improvement of docetaxel-based therapy of advanced prostate cancer

    … prostate cancer (mPCa) is currently incurable. Docetaxel-based chemotherapy, used as first-line treatment for advanced PCa, is marginally effective. As PCa is a heterogeneous disease, use of therapeutics targeting multiple pathways may improve its treatment outcome. Aneustat is first-of-a-class …

    ubc Repository record for Potential use of Aneustat for improvement of docetaxel-based therapy of advanced prostate cancer (opens in a new tab) Download PDF for Potential use of Aneustat for improvement of docetaxel-based therapy of advanced prostate cancer (opens in a new tab)

  12. Docetaxel Nanostructured lipid carrier with enhanced blood brain barrier permeability for targeted glioblastoma therapy

    … agents to pass the blood-brain barrier (BBB). Docetaxel a hydrophobic anticancer drug used alone and in combination with other drugs to treat tumours is a P-glycoprotein substrate and suffers from the drawback of non-specific cytotoxicity and limited accumulation in the brain. To address these …

    cent-lancashire Download PDF for Docetaxel Nanostructured lipid carrier with enhanced blood brain barrier permeability for targeted glioblastoma therapy (opens in a new tab)

  13. Wirksamkeit und Toxizität von Docetaxel in der Therapie von Malignomen des Kopf-Hals-Bereichs

    … Untersuchung der Effektivität und Toxizität von Docetaxel im Rahmen einer Kombinationschemotherapie mit Cisplatin und 5-Fluorouracil in unterschiedlichen Therapieansätzen bei Patienten mit einem diagnostizierten Plattenepithelkarzinom im Kopf-Hals- Bereich an der Charité Universitätsmedizin. …

    fu-berlin Repository record for Wirksamkeit und Toxizität von Docetaxel in der Therapie von Malignomen des Kopf-Hals-Bereichs (opens in a new tab)

  14. RNA HELICASE, DP103 AS A PREDICTIVE BIOMARKER FOR DOCETAXEL RESPONSE IN ERa-POSITIVE BREAST CANCER

    … IN A RETROSPECTIVE PHASE II STUDY INVOLVING DOCETAXEL BASED NEOADJUVANT THERAPY, CLINICAL RESPONDERS WERE CHARACTERIZED BY A PROGRESSIVE DECREASE IN DP103 EXPRESSION. THIS DECREASE IN DP103 EXPRESSION WAS ONLY OBSERVED IN RESPONDERS WITH ERA-POSITIVE STATUS AND NOT ERA-NEGATIVE STATUS. …

    nus Repository record for RNA HELICASE, DP103 AS A PREDICTIVE BIOMARKER FOR DOCETAXEL RESPONSE IN ERa-POSITIVE BREAST CANCER (opens in a new tab) Download file for RNA HELICASE, DP103 AS A PREDICTIVE BIOMARKER FOR DOCETAXEL RESPONSE IN ERa-POSITIVE BREAST CANCER (opens in a new tab)

  15. Development of a nanoparticulate formulation of docetaxel for the treatment of non-muscle-invasive bladder cancer

    … nanoparticulate carriers of docetaxel (DTX) offered an improved and effective formulation of the drug for intravesical delivery in mice. The present work describes the effect of concentration and exposure times of three HPG-C₈/₁₀-MePEG-NH₂’s with increasing degrees of …

    ubc Repository record for Development of a nanoparticulate formulation of docetaxel for the treatment of non-muscle-invasive bladder cancer (opens in a new tab) Download PDF for Development of a nanoparticulate formulation of docetaxel for the treatment of non-muscle-invasive bladder cancer (opens in a new tab)

  16. Contribuição da expressão de c-kit na aquisição de quimiorresistência ao docetaxel no câncer de próstata

    … dessa neoplasia ao agente quimioterápico Docetaxel. Métodos: estudo experimental, utilizando células PC3, derivadas de metástases de câncer de próstata humano andrógeno-independente e C42b derivadas de metástases ósseas de câncer de próstata de coluna lombar de ratos atímicos . Ambas …

    brazil-ufrgs Repository record for Contribuição da expressão de c-kit na aquisição de quimiorresistência ao docetaxel no câncer de próstata (opens in a new tab)

  17. Evaluation of the combination treatment docetaxel and JQ1 in 2D and 3D preclinical models of prostate cancer

    … than JQ1 alone. This study shows that JQ1 and docetaxel might serve as an effective combination therapy for patients with mPCa. We assessed the combination therapy in 2D and 3D preclinical models, and we also evaluated the susceptibility of 2D-cultured LNCaP cells and 3D-cultured LNCaP …

    fu-berlin Repository record for Evaluation of the combination treatment docetaxel and JQ1 in 2D and 3D preclinical models of prostate cancer (opens in a new tab)

Page 1 of 13